Expectant management of localized prostatic cancer

W. F. Whitmore, J. A. Warner, I. M. Thompson

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Seventy-five patients with clinical Stage B histologically proven prostatic cancer accumulated over a 40-year period and receiving no therapy for at least 1 year after histologic diagnosis were retrospectively reviewed. Twenty-nine patients had Stage B1 lesions, 37 had B2, and nine had B3 lesions; median follow-up for these s was 124, 120, and 96 months, respectively. Five ultimately received pelvic lymph node dissection with iodine-125 implantation, 23 had transurethral resection of the prostate, and 18 had endocrine therapy. Of those tumors which progressed, 18 of 19 (95%) B1, 26 of 29(90%) B2, and four of four (100%) B3 lesions demonstrated local progression first. Six of 29 (21%) B1, 17 of 37 (46%) B2, and two of nine (22%) B3 tumors developed recognized distant metastasis. Actuarial survival at 15 years was 67%, 39%, and 63% for patients with B1, B2, and B3 lesions, respectively. These data indicate the varied and potentially protracted course of patients with clinical Stage B prostatic cancer.

Original languageEnglish (US)
Pages (from-to)1091-1096
Number of pages6
JournalCancer
Volume67
Issue number4
StatePublished - 1991
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Transurethral Resection of Prostate
Lymph Node Excision
Iodine
Neoplasms
Neoplasm Metastasis
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Whitmore, W. F., Warner, J. A., & Thompson, I. M. (1991). Expectant management of localized prostatic cancer. Cancer, 67(4), 1091-1096.

Expectant management of localized prostatic cancer. / Whitmore, W. F.; Warner, J. A.; Thompson, I. M.

In: Cancer, Vol. 67, No. 4, 1991, p. 1091-1096.

Research output: Contribution to journalArticle

Whitmore, WF, Warner, JA & Thompson, IM 1991, 'Expectant management of localized prostatic cancer', Cancer, vol. 67, no. 4, pp. 1091-1096.
Whitmore WF, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991;67(4):1091-1096.
Whitmore, W. F. ; Warner, J. A. ; Thompson, I. M. / Expectant management of localized prostatic cancer. In: Cancer. 1991 ; Vol. 67, No. 4. pp. 1091-1096.
@article{a3ccb2d3185d449ca888ba49233a78b9,
title = "Expectant management of localized prostatic cancer",
abstract = "Seventy-five patients with clinical Stage B histologically proven prostatic cancer accumulated over a 40-year period and receiving no therapy for at least 1 year after histologic diagnosis were retrospectively reviewed. Twenty-nine patients had Stage B1 lesions, 37 had B2, and nine had B3 lesions; median follow-up for these s was 124, 120, and 96 months, respectively. Five ultimately received pelvic lymph node dissection with iodine-125 implantation, 23 had transurethral resection of the prostate, and 18 had endocrine therapy. Of those tumors which progressed, 18 of 19 (95{\%}) B1, 26 of 29(90{\%}) B2, and four of four (100{\%}) B3 lesions demonstrated local progression first. Six of 29 (21{\%}) B1, 17 of 37 (46{\%}) B2, and two of nine (22{\%}) B3 tumors developed recognized distant metastasis. Actuarial survival at 15 years was 67{\%}, 39{\%}, and 63{\%} for patients with B1, B2, and B3 lesions, respectively. These data indicate the varied and potentially protracted course of patients with clinical Stage B prostatic cancer.",
author = "Whitmore, {W. F.} and Warner, {J. A.} and Thompson, {I. M.}",
year = "1991",
language = "English (US)",
volume = "67",
pages = "1091--1096",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Expectant management of localized prostatic cancer

AU - Whitmore, W. F.

AU - Warner, J. A.

AU - Thompson, I. M.

PY - 1991

Y1 - 1991

N2 - Seventy-five patients with clinical Stage B histologically proven prostatic cancer accumulated over a 40-year period and receiving no therapy for at least 1 year after histologic diagnosis were retrospectively reviewed. Twenty-nine patients had Stage B1 lesions, 37 had B2, and nine had B3 lesions; median follow-up for these s was 124, 120, and 96 months, respectively. Five ultimately received pelvic lymph node dissection with iodine-125 implantation, 23 had transurethral resection of the prostate, and 18 had endocrine therapy. Of those tumors which progressed, 18 of 19 (95%) B1, 26 of 29(90%) B2, and four of four (100%) B3 lesions demonstrated local progression first. Six of 29 (21%) B1, 17 of 37 (46%) B2, and two of nine (22%) B3 tumors developed recognized distant metastasis. Actuarial survival at 15 years was 67%, 39%, and 63% for patients with B1, B2, and B3 lesions, respectively. These data indicate the varied and potentially protracted course of patients with clinical Stage B prostatic cancer.

AB - Seventy-five patients with clinical Stage B histologically proven prostatic cancer accumulated over a 40-year period and receiving no therapy for at least 1 year after histologic diagnosis were retrospectively reviewed. Twenty-nine patients had Stage B1 lesions, 37 had B2, and nine had B3 lesions; median follow-up for these s was 124, 120, and 96 months, respectively. Five ultimately received pelvic lymph node dissection with iodine-125 implantation, 23 had transurethral resection of the prostate, and 18 had endocrine therapy. Of those tumors which progressed, 18 of 19 (95%) B1, 26 of 29(90%) B2, and four of four (100%) B3 lesions demonstrated local progression first. Six of 29 (21%) B1, 17 of 37 (46%) B2, and two of nine (22%) B3 tumors developed recognized distant metastasis. Actuarial survival at 15 years was 67%, 39%, and 63% for patients with B1, B2, and B3 lesions, respectively. These data indicate the varied and potentially protracted course of patients with clinical Stage B prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026059755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026059755&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 1091

EP - 1096

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -